"The Indiana Clinical Trials Center (ICTC) is a comprehensive and highly experienced clinical research site focusing primarily on Phase I - IV dermatologic clinical trials."

During the past decade, The Indiana Clinical Trials Center conducted 67 clinical trials. In the 10-year time frame, 67 clinical trials started and 57 clinical trials were completed, i.e. on average, 85.1% percent of trials that started reached the finish line to date. In the past 5 years, 28 clinical trials started and 40 clinical trials were completed. i.e. 142.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Indiana Clinical Trials Center" #1 sponsor was "Eli Lilly and Company" with 11 trials, followed by "Janssen Research & Development, LLC" with 8 trials sponsored, "Pfizer" with 7 trials sponsored, "LEO Pharma" with 6 trials sponsored and "DUSA Pharmaceuticals, Inc." with 6 trials sponsored. Other sponsors include 51 different institutions and companies that sponsored additional 43 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Indiana Clinical Trials Center" #1 collaborator was "Dermira, Inc." with 4 trials as a collaborator, "Incyte Corporation" with 2 trials as a collaborator, "Athenex, Inc." with 1 trials as a collaborator, "Basilea Pharmaceutica" with 1 trials as a collaborator and "BioClinica, Inc." with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "The Indiana Clinical Trials Center" are "Atopic Dermatitis" (19 trials), "Actinic Keratosis" (11 trials), "Plaque Psoriasis" (11 trials), "Psoriasis" (9 trials) and "Acne Vulgaris" (8 trials). Many other conditions were trialed in "The Indiana Clinical Trials Center" in a lesser frequency.

Most popular intervention types in "The Indiana Clinical Trials Center" are "Drug" (86 trials), "Other" (10 trials), "Biological" (7 trials), "Device" (5 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (38 trials), "Vehicle" (9 trials), "Lebrikizumab" (5 trials), "Guselkumab" (4 trials) and "CTP-543" (3 trials). Other intervention names were less common.

The vast majority of trials in "The Indiana Clinical Trials Center" are 92 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "The Indiana Clinical Trials Center". undefined are not yet recruiting, 6 are recruiting, 4 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 72 completed trials in The Indiana Clinical Trials Center, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in The Indiana Clinical Trials Center, 3 "Phase 1" clinical trials were conducted, 38 "Phase 2" clinical trials and 47 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".